Cannabis Regulation in the Spotlight During Midterm Elections at the Heels of Presidential Pardon; Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombian Stance to Manufacture Products at Lower Costs

President Biden issued a pardon for federally incarcerated inmates with minor marijuana possession charges, urging governors to do the same at the state level
The President also requested a reclassification of cannabis, as it is currently listed above other drugs which are key factors in the overdose epidemic
Flora Growth, through its Colombian cultivation, is producing a higher quality product at lower-than-average cost margins due to the country’s stance on cannabis regulations

With midterm elections right around the corner, voters in five states – Arkansas, Maryland, Missouri, North Dakota, and South Dakota – will determine the legality of recreational marijuana use within each state on voting day. If passed, these states will join 19 states, two territories, and D.C., which have embraced recreational marijuana use legalization. Currently, 37 states, three territories, and D.C. already recognize the legal use of cannabis for medicinal reasons. According to Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws, “When you look at ballot campaigns in the past, you’ll see that this is an issue that crosses traditional party lines. We anticipate similar outcomes this November” (https://cnw.fm/cvqld).

Early in October, President Biden released a formal statement on his goals for marijuana reform across the country. Citing how criminal records can impose unnecessary barriers to employment, housing, and educational opportunities – more disproportionately to those people of color who are more often arrested, prosecuted, and convicted. His announcement included three steps – pardoning all prior federal offenses of simple marijuana possession, urging the governors to do the same in their respective states, and initiating a review by the Secretary of Health and Human Services and the Attorney General to review the classification of marijuana, which is classified higher than drugs currently driving the overdose epidemic (https://cnw.fm/xpxsm).

President Biden’s request for the reclassification of marijuana and the pardons issued at the federal level is helping to change the landscape of the cannabis industry. An international cannabis company, Flora Growth (NASDAQ: FLGC), is focused on cannabis brand building, leveraging natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. The company operates one of the largest outdoor cultivation facilities in the world with the aim of marketing higher-quality premium products at below-market prices. Flora Growth offers low-cost cannabis cultivation, an expansive brand and product portfolio, and a strategic global distribution platform. The NASDAQ listing of the company precludes it from participating in the US domestic market for adult use presently due to federal prohibitions.

The global cannabis cultivation market was valued at $323.9 billion in 2022. The market is expected to grow at a CAGR of 21.4% from 2022 to 2030, resulting in a market valuation of $1,844.1 billion by 2030. The growing interest in legalizing cannabis for medicinal and recreational use is a driving factor in the market’s growth (https://cnw.fm/FAA2e). Liberalization of laws regarding cannabis cultivation, especially hemp cultivation, has created opportunities in the market – which Flora Growth is leveraging, with the cultivation of its product at a key Colombian farm for international markets.

Flora Growth’s Colombian cultivation provides key advantages, including location, climate, and natural resources – all of which reduce the costs of traditional cultivation. With Colombia’s administration focused on progressive cannabis regulations, Flora Growth can produce high-quality, high-margin products leveraging Colombia’s geo-advantageous location. Over 70% of all cut flowers imported into the US come from Colombia – but Flora Growth is taking it one step further by reducing the associated costs, coming in at just $.06 per gram.

For more information, visit the company’s website at www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — AOC Calls Out Biden for Excluding Undocumented Immigrants from Cannabis Pardons

Last week, Rep. Alexandria Ocasio-Cortez stated that President Joseph Biden’s cannabis pardon proclamation was limited because it exempted noncitizens, who made up most of the federal possession cases.

During the interview with Pod Save America, the congresswoman emphasized the importance of having a Democratic party that stood up for the immigrant population through the enactment of policies that were more inclusive. She argued that while the presidential pardon should be applauded, it wasn’t inclusive because the proclamation exempted convicted individuals who were undocumented. This is despite the fact that about 90% of individuals who would have benefited from the pardon had status complications.

A 2016 U.S. Sentencing Commission report shows that more than 90% of cannabis possession cases at the federal level in fiscal year 2013 took place at the Southern border. The report states that 94% of the individuals arrested were not U.S. citizens. While these stats have changed as the years have gone by, they still speak to a trend in law enforcement.

Ocasio-Cortez also discussed how individuals with citizenship issues weren’t included in Biden’s pardon, highlighting that it was discriminating against people based on their citizen statuses. The mass pardon issued by Biden only impacted about 6,000 individuals who had committed cannabis possession offenses at the federal level, as well as those who had broken the law in the District of Columbia.

The congresswoman’s sentiments are shared by activists who have also argued that the relief should be extended to individuals with sales convictions as well as immigrants. Activists with DCMJ, Last Prisoner Project and Sensible Drug Policy protested against this last week and demanded that individuals currently in federal prison for cannabis convictions that weren’t limited to simple possession also be released.

This comes after the president himself boasted that his mass pardon had changed the lives of thousands. In an interview conducted after the mass pardon’s issuance, Biden stated that he was keeping his promise to ensure that no individual was in jail for being in possession of or using cannabis. Biden also noted that once released, the records of these individuals needed to be expunged completely because not doing so would make it hard for them to be employed.

In addition to pardoning individuals, Biden also directed that the Department of Health and Human Services and the Department of Justice carry out a scheduling review to determine whether marijuana’s current classification under the Controlled Substances Act was necessary. That review could have major ramifications for companies such as Advanced Container Technologies Inc. (OTC: ACTX) that see the marijuana industry as a major part of the clientele they serve.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — German Government Approves Cannabis Legalization Framework, But EU Sign-Off Critical

The federal cabinet in Germany has approved a framework through which marijuana could be legalized in the country. However, escalating the proposal to a legalization law is subject to approval by the European Commission as well as international law.

In recent weeks, a number of details have been surfacing on local and international media indicating some of the provisions included in the legalization framework. The plan was finally tabled before the full cabinet last Wednesday and its contents became readily available to the wider public. The cabinet approved the plan, and that brings it a little closer to making its way to the country’s lawmakers for legislative approval.

Karl Lauterbach, the country’s minister of health, admitted that the proposal shouldn’t as yet been regarded as a breakthrough in drug policy reform. He said that the EU Commission has to review the framework, and a legislative bill can then be drafted from those proposals if the Commission OKs the plan. He added that the German federal government would also soon issue its own declaration indicating the status of the framework in terms of aligning with the existing international treaties on marijuana.

The minister mentioned that the country was interested in decriminalizing cannabis with a view to giving kids better protection from the drug as well as furthering public health protection objectives.

The 12-page framework indicates that individuals who are at least 18 years old would be allowed to possess up to 30 grams of marijuana as well as grow a maximum of three plants for their own personal use. Those plants will have to be enclosed so that access to them by minors is prevented. Cannabis sales would take place at stores licensed by the federal government, and pharmacies are also being considered as possible sales locations.

A previous version of this framework was leaked to the public, resulting in an uproar about the plan to put a THC threshold on all marijuana products. That limit has since been dropped in this version approved by cabinet. However, the current framework proposes that THC caps will be enforced for any marijuana products that will be sold to those between 18 and 20 years of age, while products for those older than 20 wouldn’t have a THC upper limit.

Additionally, if the proposed legalization plan is approved in its current form, all current criminal proceedings in connection to cases that would be legal under the terms of the plan would be halted and eventually closed once the legalization law starts being implemented.

The comments about obtaining EU approval have dampened the enthusiasm of legalization advocates because it isn’t clear cut whether the commission will approve the framework for implementation.

The marijuana industry around the world, including enterprises such as American Cannabis Partners, will be following developments in Germany closely because of their possible ramifications for the entire European Union bloc as well as the global cannabis industry.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) Enabling States to be Agriculture Independent, Grow Food Year-Round

Advanced Container Technologies (OTC: ACTX) is dedicated to developing, manufacturing and selling advanced cultivation equipment, proprietary packaging systems, and a variety of other products. “One of the company’s main business units is focused on selling Grow Pods, which are advanced, self-contained hydroponic containers. These innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with a controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year,” a recent article reads. “The good thing about the [Grow Pods] container is that it can give traditional farmers a niche where they can grow year-round versus three or four times per year. We can really revolutionize what’s going on in our society. People don’t realize that we get the majority of our produce through just two states – Arizona and California. By the time [food] gets across state lines, it’s already stale… We give the ability to be farm to table… There’s no reason why every state can’t be agriculture independent and growing year-round,” Shannon Illingworth, inventor of Grow Pods, is quoted as saying.

To view the full article, visit https://cnw.fm/3mNTu

About Advanced Container Technologies Inc.

Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

India Globalization Capital Inc. (NYSE American: IGC) Is ‘One to Watch’

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia
As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC based formulation on Alzheimer’s patients
The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines
Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S.

India Globalization Capital (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (“THC”) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (“NPS”) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (“CBD”)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (“PMS”) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (“IP”) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

For more information, visit the company’s website at https://igcinc.us/.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://cnw.fm/IGC

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Maintains Late 2022/Early 2023 for Full IND Application for DehydraTECH-CBD

Lexaria, through its patented DehydraTECH(TM) technology, is improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, thereby achieving an improved speed of onset, and brain absorption of APIs
Hypertension currently affects nearly 50% of all American adults, with the American Heart Association describing it as a “silent killer”, and is now being studied for its effects during pregnancy
The company has received positive feedback for its pre-Investigational New Drug meeting from the FDA and has reported that it remains on track to file its full IND application by late 2022/early 2023
It looks to capitalize on the growth of the antihypertension market, which is set to hit $40 billion by 2031, up from $30.2 billion in 2021

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been on an aggressive push to perfect its potential hypertension treatment, building on its patented DehydraTECH(TM) technology. Through improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, Lexaria can achieve an improved speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”), which is integral to the overall treatment of conditions including but not limited to hypertension.

The American Heart Association (“AHA”) has described hypertension or high blood pressure as a “silent killer,” with nearly 50% of American adults having the condition (https://cnw.fm/P7rGD). In addition, hypertension during pregnancy comes with severe short-term risks for both mothers and their offspring, although treating the condition among these individuals is still being studied.

A recent Chronic Hypertension And Pregnancy (“CHAP”) study by Tita and colleagues sought to offer more insights into hypertension treatment during pregnancy. With over 2400 participants involved, the group noted that supporting treatment of mild chronic hypertension in pregnancy improved pregnancy outcomes. According to the study’s results, this was primarily due to a reduction in preeclampsia with severe features in medically indicated preterm birth (https://cnw.fm/DG23v).

Typically, the risks associated with hypertension in pregnancy include stroke, pulmonary oedema, acute kidney injury, preeclampsia and eclampsia, placental abruption, or even death. To the offspring, the effects can include preterm birth, birth at small-for-gestational age, or even perinatal death (https://cnw.fm/wW9xF). With such risks, there is a need for effective hypertension treatments during pregnancy. Lexaria is looking to meet that demand.

Through its DehydraTECH technology, Lexaria is looking to meet the serious unmet need in the antihypertension medication market in general and during pregnancy. It aims to achieve this by directly pushing for its products and technology and licensing it for delivering fat-soluble active molecules and drugs to strategic partners worldwide.

Lexaria is also looking to capitalize on the growth of the antihypertension drugs market, which is set to hit $40 billion by 2031, up from $30.2 billion in 2021 (https://cnw.fm/VODXl). It also hopes to carve out a significant market share globally and in the United States.

Lexaria’s management is optimistic about the company’s current trajectory. It is confident that with time, its DehydraTECH-CBD for the treatment of hypertension will receive approval from the United States Food and Drug Administration (“FDA”).

The company has so far received positive feedback from its pre-Investigational New Drug meeting (“IND”). John Docherty, Lexaria’s President, has even expressed the company’s delight, citing how helpful this feedback will be in compiling and filing its IND application. As a result, Lexaria remains on track to file its full IND application with the FDA by late 2022/early 2023, as previously announced (https://cnw.fm/ytrV5).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — New Poll Shows Most Americans Think Tobacco, Alcohol More Harmful Than Cannabis

As the perception of marijuana continues to evolve, a growing number of Americans now hold the view that this prohibited substance isn’t as harmful as tobacco and alcohol, both of which are legal across the country. This sentiment was captured in a survey conducted by Monmouth University. The survey results were published last week.

The nationally representative poll found that 54% of those interviewed were convinced that alcohol was more dangerous compared to cannabis while 38% thought the two substances carried equal levels of danger. Only 7% thought marijuana was more dangerous than alcohol.

When it came to tobacco, 45% were of the view that tobacco posed greater levels of danger when compared to cannabis, while 13% were of the view that marijuana was the more dangerous of the two. An estimated 38% thought both substances carried an equal magnitude of danger.

This poll also sounded out the respondents’ thoughts about the recent marijuana pronouncements by the U.S. president, with 69% expressing solid support for the clemency and 68% thinking it would be good to allow people to legally possess small amounts of cannabis, such as those for which pardons were being granted. In terms of party affiliation, Democrats came out strongly in support of cannabis legalization at 76%, Independents were close behind at 73% while only 52% of Republicans expressed support for legalizing the substance.

This trend was also evident when the views of the survey respondents were analyzed to gauge their thoughts on the mass pardons granted by Biden. A reported 83% of professed Democrats agreed with the decision with 71% of the Independents supporting the move while Republican support was lower at 50%.

Speaking during the release of the poll results, Patrick Murray, who heads the polling institute at Monmouth University, remarked that support for cannabis legalization has been growing at a steady pace over the past two decades. According to him, Biden’s action was aligned with the wishes of the population at this moment in time.

One notable finding from this survey was that the American population didn’t have a clear grasp of how many people would be directly impacted by the president’s pardons. The survey showed 25% thought up to 1,000 people would be pardoned, 26% thought the number would be anywhere between 1,000 and 10,000, 14% thought more than 10,000 but less than 100,000 would benefit from the pardons while 7% thought this number exceeded 100,000; 29% weren’t sure how many would be pardoned. A federal government analysis indicates that 6,500 people would be eligible to be pardoned under the president’s directive.

As more people show support for legalization and as states enact their own legalization laws, the hand of the federal government may be forced soon enough to soften its prohibitionist stance and allow players such as Prime Harvest Inc. to operate legally across the country.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Biden Boasts That Marijuana Pardons Have Changed Lives of Thousands

Earlier this month, President Joseph Biden issued a mass pardon for individuals who had been convicted of simple possession of cannabis at the federal level. A full presidential pardon usually restores an individual’s state and federal civil rights and eliminates any consequences brought on by a federal conviction.

President Biden also gave a directive that the scheduling of cannabis be reviewed by the Department of Health and Human Services and the Department of Justice. The resulting recommendation may see marijuana placed in a lower schedule or descheduled altogether, which will legalize it under federal law.

The U.S. Health and Human Services and the Justice Departments have revealed that they are committed to conducting the scheduling review quickly as directed by the president.

Biden has spent the last few weeks making good on his commitment to modest reform, after more than a year without addressing marijuana issues. His actions are supported by a majority of Americans, with results from various polls showing that most supported the president’s pardon.

In a recently aired interview, Biden stated that he’d changed the lives of thousands by pardoning them, noting that he could only grant clemency for those in federal prisons. In an earlier statement, the president had stated that he was keeping his promise that no individual needed to be in jail for merely possessing or using cannabis, noting that these records, which would prevent individuals from getting employed, also needed to be completely expunged. He added that individuals who had served their time and been released needed to have access to educational opportunities as well as other re-entry services.

The president also suggested that individuals with drug convictions needed to undergo mandatory therapy as an alternative to decriminalization. However, he indicated that he wouldn’t extend his pardon to individuals who sold cannabis and noted that individuals who had been jailed for drug offenses needed to undergo mandatory treatment while in prison. This contradicts with his earlier statement to force these individuals into treatment instead of jailing them.

While the strides being made are positive, advocates would like the president to go a step further by extending relief to individuals with sales convictions. Activists with DCMJ, Last Prisoner Project and Sensible Drug Policy are calling for the president to release individuals who have been imprisoned for cannabis convictions that aren’t limited to simple possession. This comes as officials work to ensure that those who received pardons for federal cannabis offenses under Biden’s proclamation aren’t hindered from being employed in the future.

While federal prohibition persists, marijuana companies will still have few options to secure financing for their operations, and such as like REZYFi Inc. will remain lifeline of sorts to these companies that wish to grow their operations sans traditional banking services.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi, Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Tampa Alternative Products Expo To Offer A Festive Vibe Amongst Business Networking

Exhibitors, speakers, businesses, CBD and alternative products vendors, and researchers, are all invited to attend the Tampa Alternative Products Expo 2022 at the Tampa Convention Center. With over 10,000 attendees, 300+ vendors, and 20+ speakers per event, the Expo will exude a festival-like vibe for Tampa’s CBD, cannabis, and vape communities.

The event is organized by ZJ Events, with a reputation for managing the nation’s largest CBD & Hemp Summits. The Alt Pro Expo team has expanded into the alternative products sector, which is currently disrupting traditional markets. This product category includes kratom, nootropics, vapes & nicotine replacements, energy beverages, mushrooms, dietary supplements, hemp derivatives, and so on.

Exhibitors keen on showcasing their products and services at the show can contact the organizers to book their booths. This event is an excellent platform for fostering networking amongst traders, vendors, and all members of the Alternative Products realm.

“We’ve been working hard to ensure this is our largest event to date. Tampa has a lot of untapped potential here when it comes to the alternative products industry, and it’s great to share the excitement of this show with the companies and the attendees that will become part of it. However, we want to break the traditional trade show formula, so we are bringing with us a lot of contests, giveaways, games, and music for people to have a great time.” Said Nicole Beiner, Director of Business Operations & Marketing.

Alt Pro Expo offers every segment of the CBD and alternative products community in Tampa exceptional and exciting business and networking opportunities.

Some of the show’s highlights include:

General attendees and industry buyers can win over $80K in cash in giveaways during the length of the event
Money guns shooting, money booths shooting out cash to spend at the show
An exclusive Buyer’s Zone with cornhole, ping-pong, and more activities, plus a dedicated Cantina
Over 250+ vendors have signed up to exhibit products and services while offering tons of free samples for attendees to experience
A festive atmosphere where everyone can seize exciting opportunities while having fun

The event will feature an outstanding lineup of speakers and thought leaders from the CBD and Alternative products industry. There are different tiers of sponsorships available for exhibitors, each with different perks and benefits to maximize the success of their stand.

Alternative Products Expo is all set to offer an immersive experience to attendees, industry heads, and influencers who can leverage the forum to put across their viewpoints and discuss important trends and the future scope of the Alternative products segment.

Exhibitors can showcase their product lines and services at their respective booths for greater visibility. This forum offers immense exposure opportunities to businesses so that they can be discovered by potential investors looking for avenues for investment.

To learn more, please visit https://cnw.fm/f6qpK.

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Focusing on Execution and Brand Integration Following Successful Period of Strategic Investment

Flora Growth recently participated in an earnings call in which the management team discussed the company’s financials as well as its growth strategy and outlook for the remainder of fiscal 2022 as well as 2023
The company noted it had exited a period of investment and is now focusing on execution
The period of investment saw the company acquire synergistic brands that, collectively, create a direct-to-consumer house of brands, enabling the company to enter nearly any target market regardless of the legal status of cannabis
The company also invested in the infrastructure necessary for the activation of its cultivation facility in Colombia, enabling it to progressively capitalize on new market opportunities that accompanied the legalization of the export of cannabis flower

The start of the second half of fiscal 2022 on July 1 marked an important transition point for Flora Growth (NASDAQ: FLGC), an internationally focused cannabis brand builder on a mission to build a design-led collective of plant-based wellness and lifestyle brands. The company, which had previously focused on expansion driven by acquisitions and other forms of capital-intensive investments, had now entered a period of execution, as CFO Elshad Garayev and CEO Luis Merchan separately emphasized in their presentations during the company’s H1 2022 earnings call held August 15 (https://cnw.fm/mWXcN).

This ongoing execution phase rests on a solid foundation built on a bed of strategic investment strategies that were markedly different from industry peers, according to Jason Warnock, Flora Growth Chief Commercial Officer. The initial thinking by a majority of companies entering a new cannabis market, Warnock says, often involves a rush to build infrastructure and allocate capital toward constructing massive facilities in anticipation of regulatory changes that may breathe life into these investments. Unfortunately, this gamble sometimes proves unrewarding as the changes do not always materialize.

On its part, however, Flora Growth took a different approach that entailed building, through acquisitions, and activating a brand portfolio that includes JustCBD, Vessel Brands Inc., Masaya, No Hemp Co, and Mambe. The resulting house of brands has enabled the company to operate legally in the United States despite the federal illegality of cannabis and the company’s NASDAQ listing, which precludes it from participating in the US domestic market. Additionally, it has ensured Flora Growth does not lock its capital expenditure (“CapEx”) in infrastructure that does not yield returns in the short or long term.

Moreover, and by integrating each brand into its operations, Flora Growth has created a collective capable of capitalizing on emerging opportunities in different parts of the world. This has, in turn, allowed the company to expand its global reach while navigating the different regulatory environments in the different target markets, as Flora Growth Chief Marketing Officer Jessie Casner explained in her presentation.

“Flora Growth’s House of Brands enables the company to enter nearly any target market regardless of the legal status of cannabis or its derivatives because of the diversity of its product offerings. This means Flora can begin to build a customer base, distribution networks, and supply chains in these regions in advance of movements on cannabis regulations affording us a revenue-generating infrastructure that positions us for the future,” said Casner.

But the House of Brands is just one pillar of the company’s growth strategy. The other, its commercial operation, includes a cultivation facility located on a 247-acre property in Bucaramanga, Colombia, and Flora Labs, the company’s manufacturing and R&D centers, located in Bogota and Bucaramanga, Colombia and Fort Lauderdale, Florida, that produce pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. (The company also has a life sciences division that constitutes its third growth pillar.)

On April 1, following the passing of Resolution 539, which authorizes the export of cannabis flower from Colombia (https://cnw.fm/DFZoH), Flora Growth commenced the full activation of its cultivation facility. Specifically, the company began cultivating different strains of the cannabis plant for export, departing from its previous focus on the cultivation of cannabis for use in the development of derivative products. According to the earnings call, the company has so far cultivated 8 hectares, five of which support high THC strains of cannabis while the rest support high CBD strains of the plant.

“We continue to invest in the necessary infrastructure of our cultivation and commercial pillar, which up until this point had been in development. We can now realize the value of that investment heading into the second half of 2022 and into 2023. With the activation of this pillar, we are now one of only a handful of companies that are actively moving cannabis-derived products across the globe. We expect that flow of goods to increase substantially in the coming months as we continue to build relationships with regulatory agencies in the governments around the world,” commented Flora Growth CEO Luis Merchan.

For more information, visit the company’s website at www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.